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ABSTRACT Nerve growth factor (NGF) treatment of rat
pheochromocytoma (PC12) cells induces the synthesis of the
transcription factor c-Fos, which becomes highly phosphory-
lated relative to that produced as a result of depolarization of
the cell. A peptide derived from the carboxyl terminus of c-Fos
(residues 359-370, RKGSSSNEPSSD) containing putative
phosphorylation sites was used to detect a NGF-stimulated Fos
kinase. NGF treatment of PC12 cells resulted in a rapid
activation of a protein kinase which phosphorylated both the
c-Fos peptide and authentic c-Fos at its carboxyl terminus. The
kinase was selectively activated by NGF and epidermal growth
factor but was not induced by depolarization or other agents.
The c-Fos peptide was phosphorylated at a serine correspond-
ing to Ser', a site critically implicated in the capacity of c-Fos
to exhibit transrepressive activity [Offr, R., Dwarki, V. J.,
Rashid, D. & Verma, I. M. (1990) Nature (London) 348,
80-82)]. The NGF-stulated Fos kinase may play an impor-
tant role in regulating the expression and transforming poten-
tial of c-Fos.
The protooncogene c-fos is one member of a class of imme-
diate early genes that are rapidly and transiently induced
upon treatment of rat pheochromocytoma (PC12) cells with
nerve growth factor (NGF) or a number of other agents (1).
The c-fos gene product, c-Fos, is a transcriptional regulator,
mediating transactivation by interacting with AP-1 sites as a
heterodimer with c-Jun (2-7). Two amino-terminal domains
are necessary for transactivation: a basic DNA-binding do-
main and a leucine zipper domain through which c-Fos
associates with c-Jun (8-10). In addition to its role as a
transactivator, c-Fos can repress transcription from its own
promoter, as well as from those of other immediate early
genes (4, 11-13). This transrepressive function of c-Fos is
independent of the basic region and leucine zipper and is
mediated by the carboxyl terminus of this protein (11, 12). A
c-Fos mutant lacking the carboxyl-terminal 27 amino acids
(residues 355-381) cannot repress transcription (11). v-Fos,
the oncogenic viral cognate of c-Fos, contains both the
leucine zipper and DNA-binding domains-and maintains the
ability to transactivate over AP-1 sites. However, v-Fos
differs from c-Fos due to a deletion-induced frameshift re-
sulting in 48 unrelated amino acids at the carboxyl terminus
(13, 14). Like c-Fos mutants lacking the carboxyl terminus,
the v-Fos protein does not exhibit transrepressive activity
(15). c-Fos contains potential phosphorylation sites at its
carboxyl terminus that are absent in v-Fos, one of which is
phosphorylated in vivo (16, 17). Phosphorylation of c-Fos at
sites in the carboxyl-terminal region is increased upon serum
stimulation of rat 208F cells (16).
NGF treatment of PC12 cells results in the stimulation of
the Trk protein-tyrosine kinase (18, 19), initiating a signal
transduction cascade and the serial activation of a number of
protein kinases (20-23). As a result, many proteins show
increased levels of phosphorylation, including c-Fos (24).
Curran and Morgan (24) reported that NGF treatment of
PC12 cells resulted in the hyperphosphorylation of newly
synthesized c-Fos protein relative to cells in which Fos
synthesis was stimulated by membrane depolarization, sug-
gesting the existence of a NGF-regulated Fos kinase. This
observation provoked us to search for a NGF-regulated
protein kinase that phosphorylates c-Fos. We describe here
a rapidly activated, NGF-sensitive protein kinase that phos-
phorylates the carboxyl terminus of c-Fos, a locus shown to
be involved in the transrepressive activity of this molecule
(25). We have identified the phosphorylated residue within
the peptide substrate as that corresponding to Ser362.
EXPERIMENTAL PROCEDURES
Materials. NGF was prepared by the method of Smith et al.
(26). Radiolabeled ATP was synthesized by using Gamma
Prep A (Promega). The c-Fos peptide, comprising residues359-370 (RKGSSSNEPSSD), was synthesized at facilities at
the Medical University ofSouth Carolina (Charleston) and by
Coast Scientific (La Jolla, CA). c-Fos and Fos AF proteins,
a gift ofTom Curran (Hoffmann-La Roche), were expressed
in Escherichia coli as a His6 fusion protein as described by
Abate et al. (27).
Fos Kinase Isolation. PC12 cells were grown in Dulbecco's
modified Eagle's medium supplemented with 10% horse
serum and 5% fetal bovine serum in an atmosphere of 10%o
CO2. The cells were collected by trituration in phosphate-
buffered saline containing bovine serum albumin (1 mg/ml)
and glucose (1 mg/ml), resuspended at a concentration of 2
x 106 cells per ml, and treated as described for the indicated
period of time. After collection by centrifugation, the cells
were lysed by sonication in 20mM Tris, pH 7.4/1mM EGTA,
pH 7.4/100 ,uM sodium orthovanadate (lysis buffer) contain-
ing 10 mM p-nitrophenyl phosphate, essentially as described
by Smith et al. (28). The cellular lysate was centrifuged at
100,000 x g and the supernatant was collected. The soluble
cell lysate was applied to a Mono Q HR 5/5 column (Phar-
macia) in lysis buffer and developed with a 0-0.4 M NaCI
gradient. The peak of activity eluted at 0.18 M NaCl was
collected, pooled, and dialyzed in 20 mM Hepes, pH 6.8/1
Abbreviations: NGF, nerve growth factor; ERK, extracellular sig-
nal-regulated kinase; MAPK, mitogen-activated protein kinase;
SRE, serum response element; SRF, serum response factor.
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mM EGTA/100 AM sodium orthovanadate. The sample was
then applied to a Mono S HR 5/5 column equilibrated in the
same buffer and developed with a 0-0.4 M NaCl gradient.
Kinase Assays. Kinase reactions were performed in tripli-
cate using 1 Ag of protein per sample, or 40 A.l of column
fractions, in lysis buffer containing 0.5 mM c-Fos peptide, 1.2
mM dithiothreitol, 20 ,uM [-32P]ATP (6.6 cpm/fmol), and 10
mM MgCI2 at 220C for 30 min. Reactions were stopped by
addition of trichloroacetic acid (3.7%, wt/vol) and 10 jug of
bovine serum albumin. The samples were cooled to 40C for
15 min and centrifuged for 5 min. The supernatants were
applied to Whatman P81 paper in triplicate and washed four
times for 10 min in 75 mM phosphoric acid, and incorporated
radioactivity was measured (28). Fos protein phosphoryla-
tion was evaluated by incubation as described above, except
that [32P]ATP specific activity was 13.2 cpm/fmol and reac-
tions were stopped by the addition of 3x Laemmli sample
buffer. Products were resolved by SDS/10% PAGE and
visualized by autoradiography.
Sequencing of Radiolabeled c-Fos Peptide. The c-Fos pep-
tide (25 nmol) was incubated with Fos kinase under the same
reaction conditions as described above, except that [32P]ATP
specific activity was 528 cpm/fmol. After 1 hr, the reaction
mixture was diluted into 2 ml of 0.05% trifluoroacetic acid
and loaded onto a Pharmacia Super-Pac Pep-S HPLC col-
umn. The column was washed with 5 column volumes of
0.05% trifluoroacetic acid and the peptide was eluted in 20%o
acetonitrile containing 0.05% trifluoroacetic acid. The radio-
labeled peptide was covalently attached to arylamine-
derivatized poly(vinylidene difluoride) membranes (Sequa-
lon-AA; Millipore) according to the manufacturer's instruc-
tions, using water-soluble carbodiimide. The membranes
were analyzed by sequencing in a model 473A automatic
protein sequencer (Applied Biosystems). Cycles were mod-
ified to extract the anilinothiazolinone derivatives with liquid
trifluoroacetic acid followed by n-butyl chloride/ethyl ace-
tate (1:1, vol/vol) containing 0.01% (vol/vol) phosphoric
acid. The amino acid derivatives at each cycle were collected
directly into scintillation vials, mixed with 10 ml of liquid
scintillant (National Diagnostics, Manville, NJ), and mea-
sured in a scintillation counter.
RESULTS
NGF treatment of PC12 cells resulted in the activation of a
protein kinase that phosphorylated a synthetic peptide cor-
responding to the carboxyl terminus of c-Fos (residues 359-
370). NGF maximally activated the enzyme within 5 min and
the activity remained elevated at least 2-fold up to 2 hr later
(Fig. 1). Fos kinase activity was elevated throughout the
period during which c-Fos is actively synthesized (24), con-
sistent with phosphorylation of the nascent protein by this
enzyme.
The Fos kinase was activated in response to NGF and
epidermal growth factor to approximately the same levels
(Fig. 2). Basic fibroblast growth factor, dibutryl cAMP,
phorbol 12-myristate 13-acetate, or depolarization ofthe cells
with KCI had little or no effect upon kinase activation. The
finding that Fos kinase activity was not stimulated following
depolarization is consistent with the observation of Curran
and Morgan (24) that the c-Fos protein produced in response
to depolarization was hypophosphorylated relative to that
generated following NGF treatment.
A major concern was that the Fos kinase represented
another known protein kinase that exhibited activity toward
the c-Fos peptide substrate. We have attempted to rule out
the involvement of other protein kinases based on assays for
their activities or immunological cross-reactivity (L.K.T. and
G.E.L., unpublished work). Fos kinase was partially purified
by ion-exchange chromatography on a Mono Q column. The
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FIG. 1. Time course of NGF activation of Fos kinase. PC12 cells
were treated with NGF (50 ng/ml) for the indicated time. Fos kinase
activity was measured following partial purification by Mono Q
chromatography. Data are expressed as cpm Of 32p incorporated into
c-Fos peptide (mean ± SD, measured in triplicate).
NGF-stimulated Fos kinase was eluted at 0.18 M NaCl and
was well resolved from p42 mitogen-activated protein kinase
(MAPK, also known as extracellular signal-regulated kinase
1, ERK1) and p44 MAPK (ERK2), which were eluted at 0.15
and 0.22M NaCl, respectively. Similarly, Fos kinase was not
coeluted with the major peak of Kemptide kinase activity.
Immunoblot analysis using anti-p85rsk antibodies demon-
strated that this enzyme was eluted from the column in a peak
prior to Fos kinase. Chromatography on the Mono S column
allowed clear resolution of Fos kinase from kinases phos-
phorylating the S6 peptide substrate, as well as contaminating
Kemptide kinase activity. These enzymes were of concern
due to sequence similarity between these peptide substrates
and the c-Fos peptide. We estimate a 2000-fold purification of
the Fos kinase following Mono S chromatography.
The partially purified, NGF-stimulated, Fos kinase phos-
phorylated authentic c-Fos protein. c-Fos was phosphory-
lated when combined with Fos kinase obtained from NGF-
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FIG. 2. Ligand specificity of Fos kinase. PC12 cells were treated
with NGF (50 ng/ml), epidermal growth factor (EGF, 5 ng/ml), basic
fibroblast growth factor (FGF, 30 ng/ml), dibutyryl cAMP (1 mM),
KCI (50 mM), or phorbol 12 myristate 13-acetate ["12-tetradeca-
noylphorbol 13-acetate" (TPA), 50 ng/ml] for 5 min. Fos kinase
activity was assayed following Mono Q chromatography. Data are
expressed as cpm incorporated into c-Fos peptide (mean ± SD of
triplicate measurements).
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FIG. 3. Phosphorylation of c-Fos. Fos kinase (-6 ng) from
control or NGF-stimulated cells was incubated alone (lanes a), with
1.8 pmol of c-Fos (lanes b), or with 1.8 pmol of Fos AF (lanes c) and
the phosphorylation reaction was carried out for 60 min. Proteins
were fractionated by SDS/10W PAGE and visualized by autorad-
iography. Positions of the molecular size (kDa) standards are shown.
treated cells, but not that from untreated cells (Fig. 3, lanes
b). To verify that Fos kinase phosphorylated Fos principally
at the carboxyl terminus, a deletion mutant lacking the
carboxyl-terminal 80 amino acids, Fos AF, was assayed (28,
29). The Fos AF protein was not significantly phosphorylated
(Fig. 3, lanes c). Chromatography ofthe enzyme on the Mono
S ion-exchange column demonstrated coelution of kinase
activity phosphorylating both the peptide substrate and c-Fos
protein (Fig. 4). The Fos AF substrate was phosphorylated at
very low levels by a contaminating kinase that demonstrated
a different elution profile than the c-Fos kinase. We consis-
tently observed a 90-kDa phosphoprotein after in vitro kinase
reactions using the partially purified Mono S fraction. While
the molecular mass of this species is similar to the 90 kDa
determined by gel filtration of Fos kinase, we have not
established whether this species possesses a kinase activity
(L.K.T. and G.E.L., unpublished work).
The site at which Fos kinase modified the peptide substrate
was determined by microsequencing of the phosphorylated
peptide. Fos kinase phosphorylated the c-Fos peptide at
Ser362 as demonstrated by release of radioactivity in cycle 4
(Fig. 5). The radioactivity released in cycle 1 was due to
residual [32P]ATP. The radioactivity present in cycle 5 was
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FIG. 4. Cation-exchange chromatography of Fos kinase. NGF-
stimulated Fos kinase activity obtained following chromatography
on a Mono Q column was applied to a Mono S column and developed
with a 0-0.4 M NaCl gradient. Column fractions were then assayed
alone (lanes a) or in the presence of 1.8 pmol of Fos (lanes b) or 1.8
pmol of Fos AF (lanes c). Proteins were separated by SDS/10%
PAGE. Fos peptide kinase assays were performed in parallel with
fractions obtained from control (o) or NGF-treated (e) cells. Data are
expressed as the mean + SD of triplicate determinations.
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FIG. 5. Sequence analysis of the phosphorylated c-Fos peptide.
Fos kinase isolated by Mono Q and Mono S chromatography was
incubated with c-Fos peptide, and the phosphorylated peptide was
subjected to microsequencing. Data are expressed as cpm released
from the peptide per cycle. Amino acids identified in cycles 1-12 (left
to right) are represented by standard one-letter symbols.
most likely due to incomplete peptide bond cleavage in the
previous cycle.
DISCUSSION
An increase in c-fos transcription is a common response in a
number of cell types to a variety of stimuli. The c-fos gene
product can participate in both the activation and repression
of transcription. The ability of c-Fos to differentially regulate
gene expression is central to its capacity to affect cell growth,
differentiation, and transformation. It is not presently clear
how these multiple effects of c-Fos are achieved; however,
phosphorylation of Fos and other transcription factors is
likely to be a prevalent mechanism through which their
activities are regulated. The protein kinases responsible for
these regulatory phosphorylations are important in the hor-
monal control of cellular phenotype.
We have identified a NGF-regulated Fos kinase in PC12
cells. Fos kinase was distinct from previously described
NGF-stimulated kinases. Fos kinase was not cAMP-
dependent kinase, as it was not inhibited by IP20 (at con-
centrations up to 1 gM), a specific peptide inhibitor of this
enzyme, and cAMP-dependent kinase displays different
chromatographic behavior (30, 31). Although c-Fos is phos-
phorylated in vitro at its carboxyl terminus by cAMP-
dependent kinase (31), dibutyryl cAMP treatment of PC12
cells did not result in increased Fos kinase activity toward the
peptide substrate. As previously indicated, Fos kinase was
eluted separately from MAPKs (ERKs) on ion-exchange
chromatography and did not phosphorylate their substrates,
myelin basic protein and microtubule-associated protein 2.
The PSSD motif in the Fos peptide has been identified as a
potential casein kinase II site due to its similarity to the casein
kinase II phosphorylation site in serum response factor (SRF;
ref. 32). However, Fos kinase was not inhibited by heparin up
to 1 uM, indicating that Fos kinase was not casein kinase II.
This is consistent with the observations of Abate et al. (31)
showing that casein kinase II does not phosphorylate c-Fos
in vitro. Fos kinase was distinct from protein kinase C, as it
was not stimulated by phorbol ester and had no requirement
for Ca2+. Similarly, the absence of a dependence upon Ca2+
also indicated that calmodulin kinases were not responsible
for this activity. Antibodies to the S61I kinase family failed to
precipitate Fos kinase activity (L.K.T. and G.E.L., unpub-
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lished work). Moreover, the activation kinetics and chro-
matographic behavior of Fos kinase were inconsistent with
previously reported S6 kinases in PC12 cells (20). While Fos
kinase is implicated in c-Fos phosphorylation, given its rapid
activation, it is also likely to phosphorylate other substrates.
The carboxyl terminus of c-Fos is essential for the tran-
scriptional repression exhibited by this protein (18, 26). Ofir
et al. (25) provided evidence that phosphorylation of serine
residues contained within the peptide employed in the pre-
sent study are necessary for transrepression. Substitution of
alanine residues within the GSSS sequence (residues 361-
364) inhibited the transrepressive activity of c-Fos, which
was restored upon introduction of negatively charged resi-
dues into this motif (25). The phosphorylation site at the
carboxyl terminus of c-Fos has been identified as Ser362 (17),
corresponding to the phosphorylation site within the c-Fos
peptide substrate of the NGF-activated Fos kinase described
here. The requirement for the presence of this phosphoryla-
tion site for expression of transrepressive activity strongly
suggests that phosphorylation of c-Fos by a kinase with the
specificity of Fos kinase regulates this event. The potential
functional importance of phosphorylation at this locus is
demonstrated by the enhanced transforming capacity of Fos
mutants lacking serine residues 362-364 (17).
The mechanism through which c-Fos is phosphorylated at
its carboxyl terminus may be both cell type- and ligand-
specific. It has been suggested that cAMP-dependent protein
kinase mediates the phosphorylation ofFos within this motif,
based on the ability of this kinase to phosphorylate this site
in vitro and the observation that c-Fos becomes phosphory-
lated following forskolin treatment of JEG3 cells (17, 31).
However, dibutyryl cAMP treatment of CHO cells had no
effect on c-Fos phosphorylation (16). NGF does not cause an
increase in cAMP levels in PC12 cells (33), suggesting cAMP-
dependent kinase is unlikely to be responsible for the result-
ing phosphorylation of c-Fos. It is likely that multiple,
alternative mechanisms exist that activate the transrepres-
sive function of this transcription factor.
The mechanism(s) through which c-Fos exerts its transre-
pressive activity is presently unclear. The CarG [CC(A+T-
rich),GG sequence motif] elements of the serum response
element (SRE) in the Fos promoter are required for transre-
pression. However, c-Fos does not directly interact with this
DNA motif (11). A protein complex of SRF and p62TCF binds
to the SRE and is responsible for increased c-fos transcrip-
tion following growth factor or serum stimulation (34-37). It
is hypothesized that a protein-protein interaction between
newly synthesized c-Fos and the SRF/p62TCF complex
downregulates c-fos transcription. The phosphorylation of
c-Fos at its carboxyl terminus by Fos kinase is thought to
render it able to participate in such an interaction. Consistent
with involvement of newly synthesized c-Fos protein, ongo-
ing protein synthesis is required for the repression of c-fos
transcription following growth factor stimulation (38). Depo-
larization results in the transient transcription of c-Fos
through the cAMP/Ca2+ response element, but the period of
transcriptional activation is considerably longer (39). This
pathway is mechanistically distinct from growth factor-
induced transcriptional events mediated by the SRE (40),
suggesting that depolarization-induced c-Fos transcription
may be downregulated by alternative means. Importantly,
cellular stimuli that act through the cAMP/Ca2+ response
element to modulate transcription fail to activate Fos kinase.
Identification of a hormonally stimulated Fos kinase pro-
vides an additional link in the chain of events through which
the cell is able to rapidly alter the pattern ofgene transcription
and subsequently modulate its response to signals impinging
upon it. The Fos kinase identified here may have a wider role
in transcriptional regulatory events and in the cascade of
protein kinase activation following NGF receptor occu-
pancy.
We wish to thank Drs. Tom Curran and Cory Abate for generously
providing Fos protein. We thank Drs. K. Walsh and H.-J. Kung for
critically reviewing the manuscript and Michael Murphy for his
expert technical assistance. Dr. John Blenis provided us with the
antibody to S6 II kinase. This work was performed during the tenure
of D.R.M. as National Down Syndrome Society Science Scholar.
This work was supported by grants from the National Institutes of
Health (GM34908) and the National Science Foundation (BNS-
96302), by Public Health Service Grant CA13106, and by The Sara
Chait Memorial Foundation, New York.
1. Greenberg, M. E., Greene, L. A. & Ziff, E. B. (1985) J. Biol.
Chem. 260, 14101-14110.
2. Curran, T. & Franza, B. R. (1988) Cell 55, 395-397.
3. Distel, R. J., Ro, H. S., Rosen, B. S., Groves, D. L. & Spiegel-
man, B. M. (1987) Cell 49, 835-844.
4. Schonthal, A., Herrlich, P., Rahmsdorf, H. J. & Ponta, H.
(1988) Cell 54, 325-334.
5. Lucibello, F. C., Neuberg, M., Hunter, J. B., Jenuwein, T.,
Schuermann, M., Wallich, R., Stein, B., Schonthal, A., Herr-
lich, P. & Muller, R. (1988) Oncogene 3, 43-61.
6. Rausher, F. J., III, Voulalas, P. J., Franza, B. R., Jr. &
Curran, T. (1988) Genes Dev. 2, 1687-1699.
7. Chiu, R., Boyle, W. J., Meek, J., Smeal, T., Hunter, T. &
Karin, M. (1988) Cell 54, 541-552.
8. Turner, R. & Tjian, R. (1989) Science 243, 1689-1694.
9. Kouzarides, T. & Ziff, E. (1988) Nature (London) 336, 646-651.
10. Sassone-Corsi, P., Sisson, J. C. & Verma, I. M. (1988) Nature
(London) 334, 314-319.
11. Guis, D., Cao, X., Rausher, F. J., III, Cohen, D. R., Curran,
T. & Sukhatme, V. (1990) Mol. Cell. Biol. 10, 4243-4255.
12. Wilson, T. & Treisman, R. (1988) EMBO J. 7, 4193-4202.
13. Curran, T., Miller, A. D., Zokas, L. & Verma, I. M. (1984) Cell
36, 259-268.
14. Van Beveren, C., van Straaten, F., Curran, T., Muller, R. &
Verma, I. M. (1983) Cell 32, 1241-1255.
15. Lucibello, F. C., Lowag, C., Neuberg, M. & Muller, R. (1989)
Cell 59, 999-1007.
16. Barber, J. R. & Verma, I. M. (1987) Mol. Cell. Biol. 7, 2201-
2211.
17. Tratner, I., Ofir, R. & Verma, I. M. (1992) Mol. Cell. Biol. 12,
998-1006.
18. Kaplan, D. R., Martin-Zanca, D. & Parada, L. F. (1991) Na-
ture (London) 350, 158-160.
19. Kaplan, D. R., Hempstead, B. C., Martin-Zanca, D., Chao,
M. V. & Parada, L. F. (1991) Science 252, 554-558.
20. Heasley, L. E. & Johnson, G. L. (1989) Mol. Pharmacol. 35,
331-338.
21. Mutoh, T., Rudkin, B. B., Koizumi, S. & Guroff, G. (1988) J.
Biol. Chem. 263, 15853-15856.
22. Landreth, G. E., Smith, D. S., McCabe, C. & Gittinger, C.
(1990) J. Neurochem. 55, 514-523.
23. Gomez, N. & Cohen, P. (1991) Nature (London) 353, 170-173.
24. Curran, T. & Morgan, J. I. (1986) Proc. Nat!. Acad. Sci. USA
83, 8521-8524.
25. Ofir, R., Dwarki, V. J., Rashid, D. & Verma, I. M. (1990)
Nature (London) 348, 80-82.
26. Smith, A., Varon, S. & Shooter, E. M. (1968) Biochemistry 7,
3259-3268.
27. Abate, C., Luk, D. & Curran, T. (1990) Cell Growth Differ. 1,
455-462.
28. Smith, D. S., King, C. S., Pearson, E., Gittinger, C. K. &
Landreth, G. E. (1989) J. Neurochem. 53, 800-806.
29. Abate, C., Luk, D. & Curran, T. (1991) Mol. Cell. Biol. 11,
3624-3632.
30. Cheng, H.-C., Kemp, B. E., Pearson, R. B., Smith, A. J.,
Musconi, L., Zan Patten, S. M. & Walsh, D. A. (1986) J. Biol.
Chem. 261, 989-992.
31. Abate, C., Marshak, D. R. & Curran, T. (1991) Oncogene 6,
2179-2186.
32. Manak, J. R. & Prywes, R. (1991) Mol. Cell. Biol. 11, 3652-
3659.
33. Race, H. M. & Wagner, J. A. (1985) J. Neurochem. 44, 1588-
1592.
Biochemistry: Taylor et al.
372 Biochemistry: Taylor et al.
34. Treisman, R. (1986) Cell 46, 567-574.
35. Shaw, P. E., Schroter, H. & Nordheim, A. (1989) Cell 56,
563-572.
36. Rivera, V. M., Sheng, M. & Greenberg, M. E. (1990) Genes
Dev. 4, 255-268.
37. Graham, R. & Gilman, M. (1991) Science 251, 189-192.
Proc. Nati. Acad. Sci. USA 90 (1993)
38. Muller, R., Bravo, R., Burckhardt, J. & Curran, T. (1984)
Nature (London) 312, 716-720.
39. Kruijer, W., Schubert, D. & Verma, I. M. (1985) Proc. Nati.
Acad. Sci. USA 82, 7330-7334.
40. Sheng, M., Dougan, S. T., McFadden, G. & Greenberg, M. E.
(1988) Mol. Cell. Biol. 8, 2787-27%.
